Correction: Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease

Affiliations

• ¹ Department of Medicine, Hôpital du Sacré Coeur, University of Montréal, Montréal, QC, Canada.
• ² Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, Netherlands.
• ³ Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
• ⁴ Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
• ⁵ Lysosomal Storage Disorders Unit, University College London, London, UK.
• ⁶ Amicus Therapeutics, Cranbury, NJ, USA.
• ⁷ Baylor Scott & White Research Institute, Dallas, TX, USA. [email protected].